American Oriental Bioengineering, Inc.

Quick facts

Phase 2 pipeline

• AOBO-001 · Diabetes
  AOBO-001 is a small molecule drug that targets the SGLT2 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• American Oriental Bioengineering, Inc. portfolio CI brief
• American Oriental Bioengineering, Inc. pipeline updates RSS